|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Antibiotics for treating community acquired pneumonia in people with sickle cell diseaseMartí-Carvajal AJ, Conterno L
Bookmark this:
     more ...
SummaryLack of evidence from randomized controlled trials for the efficacy and safety of antibiotic regimens for people with sickle cell disease suffering from community-acquired pneumoniaSickle cell disease affects millions of people throughout the world. These people have a susceptibility to pneumonia as a consequence of sickle damage to the spleen. Bacteria-induced community-acquired pneumonia and the antibiotic sensitivities or resistance of these bacteria vary with geography and antibiotic prescription practice. Randomized controlled trials evaluating the efficacy, safety and dosage regimens of differing antibiotic therapies (mono and combined therapies) for community-acquired pneumonia in people with sickle cell disease could not be found.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2008 Issue 3, Copyright © 2008 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
July 19. 2006 AbstractBackgroundAs a consequence of their condition, people with sickle cell disease are at high risk of developing an acute infection of the pulmonary parenchyma called community-acquired pneumonia. Many different bacteria can cause this infection and antibiotic treatment is generally needed to resolve it. There is no standardized approach to antibiotic therapy and treatment is likely to vary from country to country. Thus, there is a need to identify the efficacy and safety of different antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. ObjectivesTo determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with sickle cell disease suffering from community-acquired pneumonia. Search strategyWe searched The Group's Haemoglobinopathies Trials Register (February 2007), which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched The Cochrane Central Register of Controlled Trials (Clinical Trials) in The Cochrane Library, MEDLINE (1966 to February 2007), EMBASE (1974 to February 2007), and LILACS (1982 to February 2007). Date of most recent searches: February 2007. Selection criteriaWe searched for published or unpublished randomized controlled trials. Data collection and analysisWe intended to summarise data by standard Cochrane Collaboration methodologies, but no eligible randomized controlled trials were identified. Main resultsWe were unable to find any randomized controlled trials on antibiotic treatment approaches for community-acquired pneumonia in people with sickle cell disease. Authors' conclusionsWe were unable to identify randomized controlled trials on efficacy and safety of the antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. Randomized controlled trials are needed to establish the optimum antibiotic treatment for this condition. |